BridgeBio Pharma Inc

BBIO: XNAS (USA)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
t?>LOCK|qBLOCK|NyN?^y&

BridgeBio Earnings: Attruby Ramp Supports Long-Term Growth Outlook

BridgeBio Pharma reported net revenue of $110.6 million in the second quarter. Attruby sales totaled $71.5 million, with 3,751 unique prescriptions written to date. However, the company missed FactSet EPS consensus by $0.16, causing shares to tumble 10% on Aug. 6.

Sponsor Center